Every year, thousands of children are diagnosed with cancer in the United States. Sherrie and Michael Wells started the Hugs for Brady Foundation to help end pediatric cancer for good.
The Hugs for Brady Foundation is a 501 (c) (3) non-profit corporation. All donations are 100% tax deductible. The Hugs for Brady Foundation has over 500 volunteers and only one part-time administrative assistant staff member.
96% of every dollar raised by the Hugs for Brady Foundation goes directly toward…
· Funding advanced Cancer Research at centers such as The Rutgers Cancer Institute of New Jersey
· Special projects such as funding the region’s first sedation-free MRI project at New York Presbyterian Morgan Stanley Children’s Hospital
· Helping families defray the costs of cancer treatment for their sick children
· Providing computers, TV’s, furniture and video games for children at oncology units like the Robert Wood Johnson Bristol-Myers Squibb Children’s Hospital’s Hematology/Oncology
· Organizing Life-Saving Blood Drives
FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
March 22nd 2024Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Immunotherapy May Address ‘Huge Need’ in Advanced Endometrial Cancer
March 22nd 2024Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.
FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
March 22nd 2024Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Immunotherapy May Address ‘Huge Need’ in Advanced Endometrial Cancer
March 22nd 2024Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.
Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer
Mirvetuximab Soravtansine Bests Chemo in HRQOL for FRα+ Ovarian Cancer
Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC
2 Commerce Drive
Cranbury, NJ 08512